DOP2020000103A - Compuestos inhibidores de tirosina cinasa de bruton (btk) - Google Patents

Compuestos inhibidores de tirosina cinasa de bruton (btk)

Info

Publication number
DOP2020000103A
DOP2020000103A DO2020000103A DO2020000103A DOP2020000103A DO P2020000103 A DOP2020000103 A DO P2020000103A DO 2020000103 A DO2020000103 A DO 2020000103A DO 2020000103 A DO2020000103 A DO 2020000103A DO P2020000103 A DOP2020000103 A DO P2020000103A
Authority
DO
Dominican Republic
Prior art keywords
btk
tyrosine kinase
inhibiting compounds
bruton tyrosine
compounds
Prior art date
Application number
DO2020000103A
Other languages
English (en)
Inventor
Lee Kuklish Steven
Khilevich Albert
Marie Partridge Katherine
James Quimby Steven
James Jr Henry Kenneth
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DOP2020000103A publication Critical patent/DOP2020000103A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a compuestos inhibidores de BTK, sales farmacéuticamente aceptables, composiciones farmacéuticas de los mismos, y métodos para usar estos compuestos, sales, o composiciones para tratar enfermedades autoinmunes tales como Artritis Reumatoide.
DO2020000103A 2017-11-06 2020-06-01 Compuestos inhibidores de tirosina cinasa de bruton (btk) DOP2020000103A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762581967P 2017-11-06 2017-11-06
PCT/US2018/058104 WO2019089512A1 (en) 2017-11-06 2018-10-30 Btk inhibitor compounds

Publications (1)

Publication Number Publication Date
DOP2020000103A true DOP2020000103A (es) 2020-09-15

Family

ID=64277913

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2020000103A DOP2020000103A (es) 2017-11-06 2020-06-01 Compuestos inhibidores de tirosina cinasa de bruton (btk)

Country Status (34)

Country Link
US (1) US11542249B2 (es)
EP (1) EP3707133B1 (es)
JP (1) JP6920553B2 (es)
KR (1) KR102410202B1 (es)
CN (1) CN111278818B (es)
AR (1) AR113796A1 (es)
AU (1) AU2018360478B2 (es)
BR (1) BR112020006749A2 (es)
CA (1) CA3080123C (es)
CL (1) CL2020001089A1 (es)
CR (1) CR20200183A (es)
CY (1) CY1124994T1 (es)
DK (1) DK3707133T3 (es)
DO (1) DOP2020000103A (es)
EA (1) EA039398B1 (es)
EC (1) ECSP20024395A (es)
ES (1) ES2904843T3 (es)
HR (1) HRP20220178T1 (es)
HU (1) HUE057987T2 (es)
IL (1) IL273778B (es)
JO (1) JOP20200104A1 (es)
LT (1) LT3707133T (es)
MA (1) MA50561B1 (es)
MD (1) MD3707133T2 (es)
MX (1) MX2020004435A (es)
PE (1) PE20201168A1 (es)
PL (1) PL3707133T3 (es)
PT (1) PT3707133T (es)
RS (1) RS62805B1 (es)
SG (1) SG11202003178PA (es)
SI (1) SI3707133T1 (es)
TW (1) TWI694995B (es)
UA (1) UA126079C2 (es)
WO (1) WO2019089512A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022533968A (ja) * 2019-05-23 2022-07-27 ノバルティス アーゲー ブルトン型チロシンキナーゼ阻害剤を使用したシェーグレン症候群を処置する方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2205564B1 (en) * 2007-10-23 2014-07-30 F. Hoffmann-La Roche AG Novel kinase inhibitors
CN103038233B (zh) * 2010-05-07 2017-06-20 吉利德康涅狄格有限公司 吡啶酮和氮杂吡啶酮化合物及使用方法
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
KR20140007954A (ko) 2011-06-10 2014-01-20 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
WO2014093230A2 (en) 2012-12-10 2014-06-19 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
GB2516303A (en) * 2013-07-18 2015-01-21 Redx Pharma Ltd Compounds
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors

Also Published As

Publication number Publication date
US20200290997A1 (en) 2020-09-17
KR102410202B1 (ko) 2022-06-22
JOP20200104A1 (ar) 2022-10-30
TW201930293A (zh) 2019-08-01
CN111278818B (zh) 2023-03-28
CN111278818A (zh) 2020-06-12
SG11202003178PA (en) 2020-05-28
PT3707133T (pt) 2022-01-27
PE20201168A1 (es) 2020-10-28
HUE057987T2 (hu) 2022-06-28
KR20200060480A (ko) 2020-05-29
CL2020001089A1 (es) 2020-10-23
AU2018360478B2 (en) 2020-09-17
IL273778B (en) 2022-06-01
UA126079C2 (uk) 2022-08-10
MX2020004435A (es) 2020-08-06
JP6920553B2 (ja) 2021-08-18
EA202090843A1 (ru) 2020-07-24
LT3707133T (lt) 2022-01-25
HRP20220178T1 (hr) 2022-04-29
ES2904843T3 (es) 2022-04-06
RS62805B1 (sr) 2022-02-28
WO2019089512A1 (en) 2019-05-09
DK3707133T3 (da) 2022-01-03
US11542249B2 (en) 2023-01-03
JP2021501749A (ja) 2021-01-21
NZ764452A (en) 2023-09-29
CR20200183A (es) 2020-05-30
PL3707133T3 (pl) 2022-04-04
AU2018360478A1 (en) 2020-04-23
BR112020006749A2 (pt) 2020-10-06
CY1124994T1 (el) 2023-01-05
EA039398B1 (ru) 2022-01-24
MD3707133T2 (ro) 2022-07-31
MA50561B1 (fr) 2022-03-31
IL273778A (en) 2020-05-31
MA50561A (fr) 2020-09-16
EP3707133A1 (en) 2020-09-16
CA3080123A1 (en) 2019-05-09
AR113796A1 (es) 2020-06-10
ECSP20024395A (es) 2020-06-30
EP3707133B1 (en) 2021-12-15
CA3080123C (en) 2021-11-09
TWI694995B (zh) 2020-06-01
SI3707133T1 (sl) 2022-02-28

Similar Documents

Publication Publication Date Title
NI201900070A (es) Compuestos heterocíclicos como inmunomoduladores
CO2020000633A2 (es) Compuestos macrocíclicos y usos de los mismos
CL2017000786A1 (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
EA201892740A3 (ru) Полифторзамещенное соединение в качестве ингибитора тирозинкиназы брутона (btk)
BR112018069612A2 (pt) compostos de pirroltriazina como inibidores de tam
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
EA201892207A1 (ru) Индолкарбоксамидные соединения
CO2017004530A2 (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1
ECSP16072941A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
NI201700055A (es) 2-amino-6-(difluorometil)-5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
CO2017005588A2 (es) 2-amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
UY37378A (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus
EA201790745A1 (ru) Трициклические соединения
ECSP18014798A (es) Inhibidores de ezh2
CL2020002275A1 (es) Compuestos diólicos de aminopirazina como inhibidores de pi3k-y.
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
EA202090183A1 (ru) Композиции, способы и получение дейтерированного домперидона
EA201790870A1 (ru) Трициклические атропоизомерные соединения
CO2017001389A2 (es) Compuestos de azetidiniloxifenilpirrolidina
BR112018007517A2 (pt) métodos para tratar esclerose múltipla usando compostos de pirimidina e piridina com atividade inibidora de btk
DOP2020000103A (es) Compuestos inhibidores de tirosina cinasa de bruton (btk)
EA201791450A1 (ru) 3,5-диаминопиразоловые ингибиторы киназы
CL2017001599A1 (es) Síntesis total de trioxacarcina dc-45-a2 y preparación de análogos de trioxacarcina
BR112017017594A2 (pt) dosagens de panobinostat para mieloma múltiplo